# Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

> **NCT02284880** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 40 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093
- **DRUG:** BIA 2-093

## Key facts

- **NCT ID:** NCT02284880
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284880, "Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02284880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*